|
1
|
Magnuson WJ, Yeung JT, Guillod PD,
Gettinger SN, Yu JB and Chiang VL: Impact of deferring radiation
therapy in patients with epidermal growth factor receptor-mutant
non-small cell lung cancer who develop brain metastases. Int J
Radiat Oncol Biol Phys. 95:673–679. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhukovsky M, Varaksin A and Pakholkina O:
Statistical analysis of observational study of the influence of
radon and other risk factors on lung cancer incidence. Radiat Prot
Dosimetry. 160:108–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Barlesi F, Mazieres J, Merlio JP,
Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I,
Westeel V, et al Biomarkers France contributors, : Routine
molecular profiling of patients with advanced non-small-cell lung
cancer: Results of a 1-year nationwide programme of the French
Cooperative Thoracic Intergroup (IFCT). Lancet. 387:1415–1426.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li Y, Chen J, He Q, Ji X, Wang X, Fan C
and Li G: Clinical efficacy of neoadjuvant chemotherapy regimens
FLEEOX vs. XELOX in patients with initially unresectable advanced
gastric cancer: A propensity score analysis. Oncotarget.
8:86886–86896. 2017.PubMed/NCBI
|
|
5
|
Goldberg SB, Gettinger SN, Mahajan A,
Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A,
Jilaveanu L, et al: Pembrolizumab for patients with melanoma or
non-small-cell lung cancer and untreated brain metastases: Early
analysis of a non-randomised, open-label, phase 2 trial. Lancet
Oncol. 17:976–983. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lazaro T and Brastianos PK: Immunotherapy
and targeted therapy in brain metastases: Emerging options in
precision medicine. CNS Oncol. 6:139–151. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Antonoff MB and D'Cunha J: Non-small cell
lung cancer: The era of targeted therapy. Lung Cancer (Auckl).
3:31–41. 2012.PubMed/NCBI
|
|
8
|
Yu Q, Guo Q, Chen L and Liu S:
Clinicopathological significance and potential drug targeting of
CDH1 in lung cancer: A meta-analysis and literature review. Drug
Des Devel Ther. 9:2171–2178. 2015.PubMed/NCBI
|
|
9
|
Xue R, Yang C, Zhao F and Li D: Prognostic
significance of CDH13 hypermethylation and mRNA in NSCLC. Onco
Targets Ther. 7:1987–1996. 2014.PubMed/NCBI
|
|
10
|
Zhang YJ, Wen CL, Qin YX, Tang XM, Shi MM,
Shen BY and Fang Y: Establishment of a human primary pancreatic
cancer mouse model to examine and investigate gemcitabine
resistance. Oncol Rep. 38:3335–3346. 2017.PubMed/NCBI
|
|
11
|
Lu S, Ye M, Ding L, Tan F, Fu J and Wu B:
Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based
chemotherapy as first-line treatments for advanced non-small cell
lung cancer in China. Oncotarget. 8:9996–10006. 2017.PubMed/NCBI
|
|
12
|
Chun SG, Hu C, Choy H, Komaki RU,
Timmerman RD, Schild SE, Bogart JA, Dobelbower MC, Bosch W, Galvin
JM, et al: Impact of intensity-modulated radiation therapy
technique for locally advanced non-small-cell lung cancer: A
secondary analysis of the NRG oncology RTOG 0617 randomized
clinical trial. J Clin Oncol. 35:56–62. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang J, Zuo Z, Zhang H, Li W and Wang K:
Comparison of clinical outcomes of VATS and SBRT in the treatment
of NSCLC. Zhongguo Fei Ai Za Zhi. 19:136–146. 2016.(In Chinese).
PubMed/NCBI
|
|
14
|
D'Oronzo S, Brown J and Coleman R: The
role of biomarkers in the management of bone-homing malignancies. J
Bone Oncol. 9:1–9. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Movsas B, Hu C, Sloan J, Bradley J, Komaki
R, Masters G, Kavadi V, Narayan S, Michalski J, Johnson DW, et al:
Quality of life analysis of a radiation dose-escalation study of
patients with non-small-cell lung cancer: A secondary analysis of
the radiation therapy oncology group 0617 randomized clinical
trial. JAMA Oncol. 2:359–367. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang QF, Zhou ZW, Ji HB, Pan WH and Sun
MZ: Value of serum marker HE4 in pulmonary carcinoma diagnosis. Int
J Clin Exp Med. 8:19014–19021. 2015.PubMed/NCBI
|
|
17
|
Girotti MR, Saturno G, Lorigan P and
Marais R: No longer an untreatable disease: How targeted and
immunotherapies have changed the management of melanoma patients.
Mol Oncol. 8:1140–1158. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu XQ, Sun Y, Lau E, Zhao M and Su SB:
Advances in synergistic combinations of Chinese herbal medicine for
the treatment of cancer. Curr Cancer Drug Targets. 16:346–356.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang H, Jiang H1, Hu X and Jia Z: Aidi
injection combined with radiation in the treatment of non-small
cell lung cancer: A meta-analysis evaluation the efficacy and side
effects. J Cancer Res Ther. 11:118–121. 2015. View Article : Google Scholar
|
|
20
|
Shtivelman E, Hensing T, Simon GR, Dennis
PA, Otterson GA, Bueno R and Salgia R: Molecular pathways and
therapeutic targets in lung cancer. Oncotarget. 5:1392–1433. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Enomoto Y, Kenmotsu H, Watanabe N, Baba T,
Murakami H, Yoh K, Ogura T, Takahashi T, Goto K and Kato T:
Efficacy and safety of combined carboplatin, paclitaxel, and
bevacizumab for patients with advanced non-squamous non-small cell
lung cancer with pre-existing interstitial lung disease: A
retrospective multi-institutional study. Anticancer Res.
35:4259–4263. 2015.PubMed/NCBI
|
|
22
|
Yin ZJ, Tu HY, Fu M, Zhong WZ, An SJ, Yan
HH, Chen HJ, Lin HR and Wu YL: Impact of menopausal status and
HER-2/neu protein on efficacy of EGFR-TKI in EGFR mutant patients
with non-small cell lung cancer. J Cancer. 9:2987–2993. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Richter I, Dvořák J, Jirásek T and Bartoš
J: The possibility of epidermal growth factor receptor inhibition
in anal cancer. Klin Onkol. 28:260–264. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Suzuki S, Dobashi Y, Sakurai H, Nishikawa
K, Hanawa M and Ooi A: Protein overexpression and gene
amplification of epidermal growth factor receptor in nonsmall cell
lung carcinomas. An immunohistochemical and fluorescence in situ
hybridization study. Cancer. 103:1265–1273. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Italiano A, Vandenbos FB, Otto J, Mouroux
J, Fontaine D, Marcy PY, Cardot N, Thyss A and Pedeutour F:
Comparison of the epidermal growth factor receptor gene and protein
in primary non-small-cell-lung cancer and metastatic sites:
Implications for treatment with EGFR-inhibitors. Ann Oncol.
17:981–985. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Eberhard DA, Giaccone G and Johnson BE;
Non-Small-Cell Lung Cancer Working Group, : Biomarkers of response
to epidermal growth factor receptor inhibitors in Non-Small-Cell
Lung Cancer Working Group: Standardization for use in the clinical
trial setting. J Clin Oncol. 26:983–994. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lakayan D, Haselberg R, Gahoual R, Somsen
GW and Kool J: Affinity profiling of monoclonal antibody and
antibody-drug-conjugate preparations by coupled liquid
chromatography-surface plasmon resonance biosensing. Anal Bioanal
Chem. 410:7837–7848. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alm El-Din MA, Farouk G, Nagy H, Abd
Elzaher A and Abo El-Magd GH: Cytokeratin-19 fragments, nucleosomes
and neuron-specific enolase as early measures of chemotherapy
response in non-small cell lung cancer. Int J Biol Markers.
27:e139–e146. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lemjabbar-Alaoui H, Hassan OU, Yang YW and
Buchanan P: Lung cancer: Biology and treatment options. Biochim
Biophys Acta. 1856:189–210. 2015.PubMed/NCBI
|
|
30
|
Jiang T and Zhou C: Research progress of
targeted therapy in non-small cell lung cancer brain metastases.
Zhongguo Fei Ai Za Zhi. 17:824–828. 2014.(In Chinese). PubMed/NCBI
|
|
31
|
Slosberg ED, Kang BP, Peguero J, Taylor M,
Bauer TM, Berry DA, Braiteh F, Spira A, Meric-Bernstam F, Stein S,
et al: Signature program: A platform of basket trials. Oncotarget.
9:21383–21395. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Clifford R, Govindarajah N, Parsons JL,
Gollins S, West NP and Vimalachandran D: Systematic review of
treatment intensification using novel agents for chemoradiotherapy
in rectal cancer. Br J Surg. 105:1553–1572. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xue F, Zhu L, Wang L and Wang Q: Serum
neuron specific enolase levels correlate with patient prognosis for
advanced lung cancer. Int J Clin Exp Med. 8:9498–9504.
2015.PubMed/NCBI
|
|
34
|
Boulmier A, Feng X, Oms O, Mialane P,
Rivière E, Shin CJ, Yao J, Kubo T, Furuta T, Oldfield E, et al:
Anticancer activity of polyoxometalate-bisphosphonate complexes:
Synthesis, characterization, in vitro and in vivo results. Inorg
Chem. 56:7558–7565. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li B, Wang Y, Zhu HX, Li JL, Hu XS, Wang
B, Hao XZ, Wang L, Zhang XR and Shi YK: Association of serum EGFR
protein concentration with the efficacy of gefitinib in the
treatment of advanced non-small cell lung cancer. Zhonghua Zhong
Liu Za Zhi. 33:431–435. 2011.(In Chinese). PubMed/NCBI
|
|
36
|
Johnson JR, Cohen M, Sridhara R, Chen YF,
Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, et
al: Approval summary for erlotinib for treatment of patients with
locally advanced or metastatic non-small cell lung cancer after
failure of at least one prior chemotherapy regimen. Clin Cancer
Res. 11:6414–6421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang L, Li Y, Li L, Wu Z, Yang D, Ma H and
Wang D: The effect of icotinib combined with chemotherapy in
untreated non-small-cell lung cancer that harbored EGFR-sensitive
mutations in a real-life setting: A retrospective analysis.
OncoTargets Ther. 11:2345–2353. 2018. View Article : Google Scholar
|
|
38
|
Filosso PL, Sandri A, Oliaro A, Filippi
AR, Cassinis MC, Ricardi U, Lausi PO, Asioli S and Ruffini E:
Emerging treatment options in the management of non-small cell lung
cancer. Lung Cancer (Auckl). 2:11–28. 2011.PubMed/NCBI
|
|
39
|
Wang J, Chen J, Guo Y, Wang B and Chu H:
Strategies targeting angiogenesis in advanced non-small cell lung
cancer. Oncotarget. 8:53854–53872. 2017.PubMed/NCBI
|
